CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells.

Kelly C Arias CardenasClinton W EnosMark R Spear Dana E AustinRaghad AlmofeezStephanie KortchakLauren PincusHua-Bei GuoSamuel DolezalJ Michael PierceEmma FurthCyrille GinesteYongjun KwonCohava Gelber

Published in: Current cancer drug targets (2024)

These data suggest that further preclinical and clinical development of CT109-SN-38 is warranted.

Keyphrases

image quality
dual energy
computed tomography
contrast enhanced
positron emission tomography
magnetic resonance imaging
electronic health record
big data
cell therapy
stem cells
machine learning
drug delivery
artificial intelligence
deep learning
structural basis
pet ct